Clinical benefit, defined as a radiologic or tumor marker response or stable disease for four or more months, was observed from as low as 20 mg/d of BRCA‐mutant group and 10 mg/d in the BRCA wild‐type group, where effective PARP inhibition of 90% or higher occurred. This evidence concerns the gene PARP1 and neoplasm.